Delving into the Latest Updates on CD99 CAR-T therapy(Bio-Raid) with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

Anti-CD99 genetically modified Autologous T-cells(Poruida)

Target

CD99

Mechanism

CD99 inhibitors(CD99 molecule (Xg blood group) inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

CD99 positive osteosarcomaCD99-positive soft tissue sarcoma

Inactive Indication-

Originator Organization

Wuhan Bio-Raid Biotechnology Co., Ltd.

Active Organization

Wuhan Bio-Raid Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhaseIND Approval

First Approval Date-

Regulation-

Login to view timeline

AbstractCAR T cell therapy has shown dramatic clinical success in relapsed or refractory B-ALL and other hematological malignancies. However, the loss of specific antigens, cell fratricide, T cell aplasia, and normal T cell separation are challenges in treating T cell leukemia/lymphoma with CAR T therapy. CD99 is a promising antigen to target T-ALL and AML as it is strongly expressed on the majority of T-ALL and AML. Here, we isolated a low-affinity CD99 (12E7) antibody, which specifically recognizes leukemia cells over normal blood cells. Moreover, T cells transduced with an anti-CD99-specific CAR that contained the 12E7 scFv expanded with minor fratricide and without normal blood cells toxicity. We observed that our anti-CD99 CAR T cells showed robust cytotoxicity specifically against CD99+ T-ALL cell lines and primary tumor cells in vitro and significantly prolonged cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) models survival in vivo. Together, our results demonstrate that anti-CD99 CAR T cells could specifically recognize and efficiently eliminate CD99+ leukemia cells.

100 Deals associated with CD99 CAR-T therapy(Bio-Raid)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CD99 positive osteosarcoma	IND Approval	CN	Wuhan Bio-Raid Biotechnology Co., Ltd.	25 Apr 2024
CD99-positive soft tissue sarcoma	IND Approval	CN	Wuhan Bio-Raid Biotechnology Co., Ltd.	25 Apr 2024